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Abstract
Background: Coronavirus disease 2019 (COVID-19) has spread to almost every region and country in the world,
leading to widespread travel restrictions and national lockdowns. Currently, there are limited epidemiological and
clinical data on COVID-19 patients from low and middle-income countries. We conducted a retrospective single-
center study of the first 100 individuals with suspected COVID-19 (between Jan. 25 and Mar. 29, 2020) admitted to
San Lazaro Hospital (SLH), the national infectious diseases referral hospital in Manila, Philippines.
Results: Demographic data, travel history, clinical features, and outcomes were summarized and compared
between COVID-19 confirmed and non-confirmed cases. The first two confirmed cases were Chinese nationals,
admitted on Jan. 25. The third confirmed case was a Filipino, admitted on Mar. 8. Trends toward confirmed COVID-
19 cases not reporting international travel and being admitted to SLH from the densely populated area of Manila
city were observed during Mar. 8-29. All 42 of the 100 confirmed COVID-19 cases were adults, 40% were aged 60
years and above and 55% were male. Three were health workers. Among individuals with suspected COVID-19,
confirmed cases were more likely to be older, Filipino, not report international travel history and have at least one
underlying disease, particularly diabetes, report difficulty in breathing, and a longer duration of symptoms. In over
90% of non-COVID-19 cases, the alternative diagnosis was respiratory. Nine (21%) confirmed cases died. The median
duration from symptoms onset to death was 11.5 (range: 8–18) days.
Conclusions: Imported COVID-19 cases have reduced but local transmission persists and there is a trend toward
cases being admitted to SLH from densely populated areas. This study highlights the difficulty in diagnosing
COVID-19 on clinical grounds and the importance of diagnostic capacity in all settings. Difficulty of breathing was
the only symptom associated with COVID-19 infection and should alert clinicians to the possibility of COVID-19.
Clinical characteristics of confirmed COVID-19 cases and a hospital case fatality rate of 21% are comparable with
other settings.
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Introduction
Coronavirus disease 2019 (COVID-19) is a respiratory
disease caused by a novel coronavirus named severe
acute respiratory syndrome coronavirus 2 (SARS-CoV-2)
[1]. Since December 2019, when initial cases were identi-
fied in Wuhan, China, COVID-19 has spread to almost
every region and country in the world, leading to wide-
spread travel restrictions and national lockdowns [1].
The World Health Organization declared a global pan-
demic on Mar. 11, 2020 [2]. The epidemiological and
clinical characteristics of COVID-19 have been well de-
scribed in a range of settings, including China, the USA,
and Singapore [3–5]. However, there are limited reports
of the epidemiological and clinical characteristics of
COVID-19 from low and middle income (LMIC) coun-
tries with tropical climates.
The first COVID-19 case in the Philippines was
confirmed on Jan. 31, 2020, admitted to San Lazaro
Hospital (SLH), the national infectious disease referral
hospital in Manila [6]. The second case was the close
contact of the first case and was the first confirmed
death in the country as well as the first mortality out-
side China. Both of the cases were imported cases
(travelers from China). The Philippine government
implemented travel restrictions on foreign travelers
from Hubei province on Jan. 31, and then extended
this to include additional countries with COVID-19
cases during February [7–9]. The first confirmed local
transmission of COVID-19 in the country, without
any travel history, was reported on Mar. 5 [10]. As of
May 2, 8772 confirmed cases were reported in the
Philippines [11]. In this study, we describe the epi-
demiological, clinical characteristics, and clinical out-
comes of the first 100 individuals with suspected
COVID-19 admitted to SLH by Mar. 31, 2020.
Methods
Study design and participants
We conducted a retrospective single-center descriptive
study summarizing the first 100 individuals with sus-
pected COVID-19 admitted to SLH, which serves a low-
income population in Manila, the most densely popu-
lated city with Metropolitan Manila, Philippines. During
this time, adult and pediatric patients with suspected
COVID-19 residing in the National Capital Region of
Manila were admitted to SLH, in addition to other hos-
pitals dedicated for COVID-19 admission in the region.
Admitted patients included either self-referrals (walk-in
patients) or referrals from other health facilities through
direct coordination or through the Regional Epidemio-
logic Surveillance Unit (RESU). From March 7, the De-
partment of Health (DOH) guidelines stated that only
confirmed COVID-19 patients that were severe or crit-
ical should be referred to SLH [12].
This was a retrospective analysis of anonymized rou-
tinely collected data. The study was approved by the
SLH research ethics and review unit (Ref: SLH-RERU-
2020-022-I) and the School of Tropical Medicine and
Global Health, Nagasaki University Ethical Committee
(NU_TMGH_2020_119_1).
Procedures
We obtained data from “Case Investigation Forms (CIF)”
for 2019 coronavirus disease completed by the clinical
teams and submitted to the SLH epidemiology depart-
ment. The CIF was designed by the Philippines DOH
Epidemiology Bureau, which evolved from the SARI (se-
vere acute respiratory illness) case report form, and col-
lected information in the following domains: patient
profile, Philippine residence, overseas employment ad-
dress (if relevant), travel history, likely exposure
(imported or local), clinical information, specimen infor-
mation final classification (COVID-19 or not COVID-
19), outcome (died or discharged). Information on
whether the patient self-referred or was referred from
another hospital was not systematically recorded. Se-
lected data were encoded to create an anonymized data-
set. Clarifications were discussed with the epidemiology
department encoders or clinical teams. The analysis was
undertaken after clinical outcomes were available for all
patients.
Case definition of COVID-19 suspect
The case definition for a suspected COVID-19 individual
in the Philippines has been modified over a short period
of time as the epidemic has evolved. The initial decision
tool released by the DOH on Jan. 21, 2020 [13], classi-
fied individuals as a suspected case, or person under in-
vestigation (PUI), if they fulfilled at least three of the
following criteria: fever, respiratory infection (cough
and/or coryza), residence or travel history to Wuhan,
Hubei, in the 14 days prior to symptom onset, or a his-
tory of exposure such as close contact with a confirmed
case [14]. The case definition was adapted on Feb. 26,
2020, with the suspected COVID-19 case criteria ex-
panded to include all areas with travel restrictions [15].
Following the onset of community transmission, on
Mar. 16, the case definition was further modified to in-
clude individuals without a travel history and added
shortness of breath to the symptom list [10]. Cases were
considered “imported” if a history of international travel
was reported within 14 days prior to the admission, and
conversely “local” if no international travel was reported
within 14 days prior to the admission.
Confirmatory test for COVID-19
Laboratory confirmation for the first COVID-19 case was
performed at the Victorian Medical Center (Australia)
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[16] and subsequently for all other cases at the Research In-
stitute for Tropical Medicine (RITM) [17]. Nasopharyngeal
and oropharyngeal swabs (NPS/OPS), and in some cases
sputum and endotracheal aspirates, were obtained from pa-
tients and maintained in viral-transport medium. COVID-
19 was confirmed by real-time PCR detecting SARS-CoV-2
at the RITM using the Corman et al. protocol [13].
Statistical analysis
We summarized demographic characteristics, travel his-
tory, symptoms on admission, co-morbidities by whether
a suspected case tested positive for COVID-19 or not.
We also summarised duration between onset of symp-
toms and admission. Continuous variables were
expressed as mean (standard deviation, SD), median
(range), and categorical variables were expressed as
number (%). Fisher’s exact test was used to test for asso-
ciations between categorical variables and Mann-
Whitney tests were used to compare discrete variables
between categories of categorical variables. All analyses
were performed using Stata v15 [18].
Results
One hundred patients with suspected COVID-19 infec-
tion admitted in SLH from Jan. 25 to Mar. 29, 2020,
were included in this study. Of these, 42 (42%) were
identified as laboratory-confirmed COVID-19. Figure 1
shows the timeline of admission of cases indicating
whether a history of international travel was reported.
The first two suspected patients were admitted on Jan.
25, 2020, both of whom became confirmed cases. During
Jan. 27-Mar. 7, a further 42 suspected cases were admit-
ted, none of whom were confirmed cases. The next con-
firmed case was admitted on Mar. 8. From Mar. 8-29, a
further 55 suspected cases were admitted, of whom 39
were confirmed cases. Figure 2 shows the approximate
residence of suspected and confirmed COVID-19 cases
admitted during Mar. 8-29, 2020, excluding those resi-
dents outside Metro Manila or staying in a hotel. During
Mar. 8-18, 14 confirmed cases resident in Metro Manila
were admitted to SLH, none of whom lived in Manila
city. During Mar. 19-29, 15 confirmed cases resident in
Metro Manila were admitted to SLH, of whom 8 lived in
Manila city.
Table 1 shows the demographic and baseline charac-
teristics of the 100 individuals with suspected COVID-
19. Most were aged over 18 (98%) and Filipino (83%).
Other nationalities included Chinese (14), American (2),
and German (1). Just over half were male (58%), 11%
were healthcare workers and recent travel history
Fig. 1 Timeline of admission date of the first 100 suspected COVID-19 cases to an infectious diseases hospital in Metro Manila. Cases were
considered “imported” if a history of international travel was reported within 14 days prior to the admission, and conversely ‘local’ if no
international travel was reported within 14 days prior to the admission
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outside of the Philippines was reported in 47% of sus-
pected cases. Around one-third of suspected cases re-
ported at least one underlying disease (31%), including
hypertension (23%), diabetes (9%), cardiovascular disease
(7%), respiratory disease (10%), and HIV (1%). One pa-
tient reported being pregnant.
Cough was the predominant symptom reported (70%),
followed by coryza and fever in around 40%, then sore
throat and difficulty of breathing in around 20% of individ-
uals with suspected COVID-19. A small number (6%) had
other symptoms which included back pain (2%), diarrhea
(2%), and body malaise (2%). The median time from onset
of symptoms to hospital admission was 4 days (0, 29).
All confirmed COVID-19 cases were adults. Con-
firmed cases were older (Fishers test p = 0.003); 40% of
confirmed cases were aged 60 years or older and a third
were 41-59 years of age. Country of travel history was as-
sociated with confirmed COVID-19 (p ≤ 0.001) and in-
creased likelihood of COVID-19 among the Filipino
population than other nationalities in this sample (p =
0.024). Confirmed COVID-19 was more common among
suspected cases with at least one underlying disease (p =
0.004), in particular, diabetes (p = 0.033) and those who
presented with difficulty breathing (p = 0.033). Con-
firmed cases had experienced symptoms for longer (me-
dian of 7 days vs 3 days, p < 0.001). Among the 42
COVID-19 laboratory-confirmed cases, 9 (21%) died
(data not shown). Among the 9 patients who died, the
median duration of hospitalization was 5 days (0, 8) and
the median duration between onset of symptoms and
outcome was 11.5 days (8, 18). The sample size did not
allow a detailed analysis of factors associated with an
outcome of discharged or died. Among the 58 non-
COVID-19 cases, 91% of the alternative diagnoses were
respiratory (upper respiratory tract infection [39],
community-acquired pneumonia [13], chronic bronchitis
[1]). Other diagnoses included cardiac (2), viral unspeci-
fied (1), gingivitis (1), and not-specified (1).
Discussion
In this study, we report the first 100 individuals with
suspected COVID-19 admitted to an infectious disease
Fig. 2 Residence of suspected and confirmed COVID-19 individuals if resident in the National Capital Region of Metropolitan Manila admitted
during 8–18 March (left) and 19–29 March (right). Twenty-two individuals were admitted during Mar. 8–18, of whom 14 were confirmed COVID-
19 (imported [5] vs. local [9]). Twenty-three individuals were admitted during Mar. 19–29 of whom 15 were confirmed COVID-19 (imported (n =
1) vs. local [n = 14]). Excludes population not resident in Metro Manila (n = 21) or admitted before March 8 (n = 34). Dots overlap in the case of
identical or similar residence and hence a separate dot is not visible for every case
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Table 1 Demographic and baseline characteristics of suspected COVID-19 patients
Characteristic All COVID-19 Not COVID-19 p value
Overall 100 42 58
Age (years) N 100 42 58
Mean (SD) 45 (19) 52 (16) 39 (19)
Median (range) 42.5 (4, 89) 56.5 (24, 89) 31.5 (4, 88) < 0.001
Age group (years) 1–5 1 (1) 0 (0) 1 (2) 0.003
6-12 0 (0) 0 (0) 0 (0)
13-18 1 (1) 0 (0) 1 (2)
19-40 47 (47) 12 (29) 35 (60)
41-59 25 (25) 13 (31) 12 (21)
60 + 26 (26) 17 (40) 9 (16)
Sex Female 42 (42) 19 (45) 23 (40) 0.682
Male 58 (58) 23 (55) 35 (60)
Nationality American 2 (2) 0 (0) 2 (3) 0.024
Chinese 14 (14) 2 (5) 12 (21)
Filipino 83 (83) 40 (95) 43 (74)
German 1 (1) 0 (0) 1 (2)
Health worker No 89 (89) 39 (93) 50 (86) 0.350
Yes 11 (11) 3 (7) 8 (14)
Recent international travel history (within 14 days prior to admission) No 53 (53) 31 (74) 22 (38) < 0.001
China 19 (19) 3 (7) 16 (28)
other Asia 24 (24) 5 (12) 19 (33)
Europe or USA 3 (3) 2 (5) 1 (2)
United Arab Emirates 1 (1) 1 (2) 0 (0)
Reported symptoms
Coryza No 59 (59) 24 (57) 35 (60) 0.838
Yes 41 (41) 18 (43) 23 (40)
Cough No 30 (30) 10 (24) 20 (34) 0.277
Yes 70 (70) 32 (76) 38 (66)
Fever No 61 (61) 24 (57) 37 (64) 0.538
Yes 39 (39) 18 (43) 21 (36)
Sore throat No 79 (79) 30 (71) 49 (84) 0.139
Yes 21 (21) 12 (29) 9 (16)
Difficulty breathing No 82 (82) 30 (71) 52 (90) 0.033
Yes 18 (18) 12 (29) 6 (10)
Other symptoms No 94 (94) 39 (93) 55 (95) 0.694
Yes 6 (6) 3 (7) 3 (5)
Co-morbidities
Cardiovascular disease No 93 (93) 38 (90) 55 (95) 0.449
Yes 7 (7) 4 (10) 3 (5)
Diabetes No 91 (91) 35 (83) 56 (97) 0.033
Yes 9 (9) 7 (17) 2 (3)
Hypertension No 77 (77) 28 (67) 49 (84) 0.053
Yes 23 (23) 14 (33) 9 (16)
Respiratory illness, including asthma No 90 (90) 35 (83) 55 (95) 0.090
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hospital in Metro Manila from Jan. 25 to Mar. 29, 2020.
For comparison, there were 2084 confirmed cases re-
ported nationally in the Philippines as of Mar. 31, 2020
[19]. Some temporal and geographic trends can be ob-
served, with regards to suspected and confirmed infec-
tions at SLH. The first two suspected COVID-19 cases
admitted to SLH on Jan. 25, 2020, were Chinese na-
tionals on vacation from Wuhan, becoming the first
confirmed COVID-19 cases in the Philippines [6]. The
Philippine government implemented travel restrictions
on foreign travelers from Hubei province on Jan. 31, and
then extended this to include additional countries with
COVID-19 cases during February [7, 8]. The DOH con-
ducted contact tracing on all the confirmed cases and
released an interim guideline for contact tracing for con-
firmed COVID-19 cases on February 5, 2020 [20]. The
absence of further confirmed cases among foreign na-
tionals suggests that these measures were effective. The
third confirmed case was admitted on Mar. 8, more than
a month after the first case. No epidemiological link was
found between the third case and the first two cases.
The third, fourth, and fifth cases all reported a history of
international travel. The case admitted on Mar. 10 was
the first case suggestive of local transmission. On Mar.
12, the Philippine government expanded the travel ban
to visitors from all 65 estimated countries with local
transmission [9]. Trends toward confirmed COVID-19
cases not reporting international travel (Fig. 1) and being
admitted from the populous area of Manila city rather
than other areas (Fig. 2) were observed during Mar. 8-
29. While only from one hospital, this data suggests the
COVID-19 epidemic may have reached Manila city dur-
ing this time period, as it is likely that symptomatic indi-
viduals would have attended SLH rather than another
hospital. Increased COVID-19 infections in Manila city
are of concern; given it is the most densely populated
city in Metro Manila, with 71,263 persons per square
kilometer [21]. Small dwelling sizes, social mixing due to
extended families, overcrowding in slums, poses a high
risk of community transmission and large outbreak in
the absence of public health interventions. In order to
suppress and mitigate transmission in the Philippines,
the government has implemented contract tracing and
surveillance, triage systems, increased testing, and im-
proved case management. Enhanced community quaran-
tine has been in place in Luzon island since Mar. 17,
2020 [19]. The effect of these interventions on commu-
nity transmission and number of severe COVID-19 cases
in the context of relatively young population in a trop-
ical climate needs to be carefully assessed.
The factors we report to be associated with COVID-19
confirmed cases among suspected cases should be inter-
preted with caution. Our finding that COVID-19 con-
firmed cases tended to be older, Filipino, and less likely
have had recent international travel history could be ex-
plained by an over-representative number of younger
cases with milder symptoms in our sample, reflecting
the evolving suspected case definition and referral
guidelines.
In over 90% of non-COVID-19 cases, the alternative
diagnosis was respiratory, highlighting the difficultly in
diagnosing COVID-19 on clinical grounds and the im-
portance of diagnostic capacity in all settings. Difficulty
of breathing was the only reported symptom associated
with COVID-19 infection. The presence of this symptom
should alert healthcare workers to the possibility of
COVID-19 infection in this setting. COVID-19 cases
were more likely to have an underlying disease, in par-
ticular diabetes and hypertension. However, for the
aforementioned reasons, these findings should be inter-
preted with caution.
Among the first 100 cases, seven health care workers
were admitted, three of whom were COVID-19 confirmed.
This highlights the importance of protecting HCWs during
the COVID-19 pandemic. This highlights the importance
of protecting HCWs during the COVID-19 pandemic. As
of Apr. 6, it has been reported that 299 HCWs have tested
positive and 10 have died in the Philippines [22]. During
Table 1 Demographic and baseline characteristics of suspected COVID-19 patients (Continued)
Characteristic All COVID-19 Not COVID-19 p value
Yes 10 (10) 7 (17) 3 (5)
HIV Unknown 99 (99) 42 (100) 57 (98) -
Yes 1 (1) 0 (0) 1 (2)
At least one underlying disease No 69 (69) 22 (52) 47 (81) 0.004
Yes 31 (31) 20 (48) 11 (19)
Pregnancy in women 1/41 (3%) 0/19 (0%) 1/22 (4%) -
Duration between onset of symptoms and admission N 97 39 58
mean (SD) 6 (6) 8 (5) 5 (6)
median (range) 4 (0, 29) 7 (0, 19) 3 (0, 29) < 0.001
Data are n (%) unless otherwise stated
p value from Fisher’s exact test for categorical variables or Mann-Whitney for continuous variables
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the same time period, there were reports of HCWs hit hard
by COVID-19 across several countries [23]. Ensuring ad-
equate supplies of personal protective equipment (PPE),
COVID-19 testing and psychological support for HCWs will
be important in order to sustain the COVID-19 response in
the country. Recently, the Philippine government had secured
a US$ 100 million loan from World Bank for COVID-19
Emergency Response including the provision of PPEs [24]. In
addition, PPE is being locally manufactured with support
from the Philippine Department for Trade and Industry [25].
The clinical characteristics of the confirmed COVID-
19 cases in this study are comparable with the early case
series from China and reports from other countries [4,
5, 24]. Cough and fever were the most common symp-
toms, similar to results reported in China, Italy, and the
USA. Shortness of breath and muscle aches were less
frequently reported in our study but may not have been
systematically recorded on the CIF [3, 26, 27].
Among the 9 patients who died, most deaths occurred
within a week of admission and within 18 days of symp-
tom onset (median 11.5 days). A range of about 2-8 weeks
from time of symptom onset to death was reported in
China early in the outbreak [28]. Recent studies also re-
port a similar range of hospitalization among the non-
survivors, with the majority requiring ICU care [29, 30].
Larger adequately powered studies to analyze risk factors
for mortality in this setting are required. Among admitted
COVID-19 cases, the case fatality rate was 21%. This is
comparable to other in-patient settings in Wuhan China
(CFR—15% and 28%) and New York (CFR—21%) [26, 31,
32]. The CFR is higher than the overall mortality rate in
the Philippines, reported to be 6.6% [33]. However, this
cannot be compared as hospitalized cases are likely to be
more severe than cases in the general population. In this
study, almost half of confirmed admitted cases were older,
had at least one co-morbidity, most commonly hyperten-
sion (33%), diabetes (17%), or respiratory illness (17%).
Older age and hypertension were reported to be key risk
factors for COVID-19 mortality in Italy [34].
This study has some limitations. First, this is a modest
case series of 100 patients with suspected COVID-19 in-
fection, of whom only 42 patients had confirmed
COVID-19 infection. The study was underpowered to
detect associations with mortality. Second, the findings
from this study cannot be generalized to other popula-
tions in the Philippines or elsewhere given the small
sample size and evolving suspected COVID-19 criteria
and heterogeneous study population. Third, this analysis
was limited to data collected on the CIFs and did not in-
clude detailed travel, referral or contact history, or infor-
mation on investigations and treatments received. Our
assumption that cases reporting recent international
travel were imported may not be true and could be coin-
cidental in some cases.
While this study provides some insights, a larger study
would help further define the epidemiology and clinical
features of COVID-19 in this setting. We would caution
against any change in patient management based on this
study. However, the data we present allows an early as-
sessment of epidemiological and clinical characteristics
of COVID-19 in Metro Manila, Philippines, and a hos-
pital in a tropical LMIC country.
Conclusion
As of May 2, there have been 3,267,184 cases confirmed
cases globally, and 8772 confirmed cases in the
Philippines [10, 35] indicating sustained community
transmission. We report an increasing trend of con-
firmed COVID-19 cases being admitted to SLH from the
densely populated Manila city area and a hospital case
fatality rate of 21%.
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